Vikram Purohit
Stock Analyst at Morgan Stanley
(1.00)
# 1,577
Out of 4,650 analysts
184
Total ratings
27.87%
Success rate
-14.92%
Average return
Main Sectors:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZBIO Zenas BioPharma | Initiates: Overweight | $40 | $20.59 | +94.27% | 1 | Oct 8, 2024 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $8.17 | +10.16% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $23.12 | +34.08% | 2 | Sep 11, 2024 | |
| SLRN Acelyrin | Maintains: Equal-Weight | $13 → $6 | $6.40 | -6.25% | 7 | Aug 19, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $59 → $64 | $50.64 | +26.38% | 6 | Aug 7, 2024 | |
| ABSI Absci | Initiates: Overweight | $7 | $4.17 | +67.87% | 1 | Jul 3, 2024 | |
| ASND Ascendis Pharma | Maintains: Equal-Weight | $116 → $140 | $126.77 | +10.44% | 18 | May 16, 2024 | |
| AXSM Axsome Therapeutics | Upgrades: Overweight | $90 → $115 | $90.35 | +27.28% | 18 | Apr 29, 2024 | |
| EXAI Exscientia | Maintains: Equal-Weight | $7 | $5.11 | +36.99% | 16 | Apr 22, 2024 | |
| ABVX ABIVAX Société Anonyme | Maintains: Equal-Weight | $15 → $16 | $10.60 | +50.94% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $6.22 | +382.32% | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $22 | $8.48 | +159.43% | 6 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $8.56 | +16.82% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $46 → $6 | $2.39 | +151.05% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $74 → $64 | $73.60 | -13.04% | 22 | Nov 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $9.06 | +363.58% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $11 | $6.74 | +63.20% | 1 | Jul 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $23 | $3.73 | +503.22% | 4 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $48.49 | -15.45% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $34.41 | +16.25% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $1.72 | +655.81% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $18.74 | +102.77% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $10.35 | +93.24% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $8.65 | +15.61% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $18 → $7 | $17.14 | -59.16% | 8 | Dec 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $4.75 | +363.16% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $4 | $0.82 | +387.80% | 2 | Aug 5, 2020 |
Zenas BioPharma
Oct 8, 2024
Initiates: Overweight
Price Target: $40
Current: $20.59
Upside: +94.27%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $8.17
Upside: +10.16%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $23.12
Upside: +34.08%
Acelyrin
Aug 19, 2024
Maintains: Equal-Weight
Price Target: $13 → $6
Current: $6.40
Upside: -6.25%
Halozyme Therapeutics
Aug 7, 2024
Maintains: Overweight
Price Target: $59 → $64
Current: $50.64
Upside: +26.38%
Absci
Jul 3, 2024
Initiates: Overweight
Price Target: $7
Current: $4.17
Upside: +67.87%
Ascendis Pharma
May 16, 2024
Maintains: Equal-Weight
Price Target: $116 → $140
Current: $126.77
Upside: +10.44%
Axsome Therapeutics
Apr 29, 2024
Upgrades: Overweight
Price Target: $90 → $115
Current: $90.35
Upside: +27.28%
Exscientia
Apr 22, 2024
Maintains: Equal-Weight
Price Target: $7
Current: $5.11
Upside: +36.99%
ABIVAX Société Anonyme
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $10.60
Upside: +50.94%
Apr 1, 2024
Initiates: Overweight
Price Target: $30
Current: $6.22
Upside: +382.32%
Feb 28, 2024
Maintains: Equal-Weight
Price Target: $20 → $22
Current: $8.48
Upside: +159.43%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $8.56
Upside: +16.82%
Nov 7, 2023
Downgrades: Equal-Weight
Price Target: $46 → $6
Current: $2.39
Upside: +151.05%
Nov 1, 2023
Maintains: Equal-Weight
Price Target: $74 → $64
Current: $73.60
Upside: -13.04%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $9.06
Upside: +363.58%
Jul 13, 2023
Maintains: Equal-Weight
Price Target: $8 → $11
Current: $6.74
Upside: +63.20%
Jun 5, 2023
Maintains: Equal-Weight
Price Target: $20 → $23
Current: $3.73
Upside: +503.22%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $48.49
Upside: -15.45%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $34.41
Upside: +16.25%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $1.72
Upside: +655.81%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $18.74
Upside: +102.77%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $10.35
Upside: +93.24%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $8.65
Upside: +15.61%
Dec 10, 2021
Downgrades: Underweight
Price Target: $18 → $7
Current: $17.14
Upside: -59.16%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $4.75
Upside: +363.16%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $8 → $4
Current: $0.82
Upside: +387.80%